Filip Janku sold $882k of GLUE
Chief Medical Officer at Monte Rosa Therapeutics, Inc.. 41,845 shares at an average of $21.08, traded Jun 23, 2026, filed Jun 25, 2026.
Score components
- +15RoleOfficer
- +23Trade size$882k at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-282740, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | MOption exercise Common Stock10b5-1 | +6,000 | $7.56 | $45k | 71,837 | Jun 25, 2026 |
| Jun 23, 2026 | SOpen-market sale Common Stock10b5-1 | -11,845 | $20.22 | $240k | 59,992 | Jun 25, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +30,000 | $7.56 | $227k | 89,992 | Jun 25, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stock10b5-1 | -30,000 | $21.42 | $643k | 59,992 | Jun 25, 2026 |
| Jun 23, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 96,000 | Jun 25, 2026 |
| Jun 24, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 66,000 | Jun 25, 2026 |
Related signals
Other insiders at Monte Rosa Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Matthew Bowen Principal Accounting Officer | $137 13 shares | -0% | |
| 52Moderate | Monte Rosa Therapeutics, Inc. | Markus Warmuth President & CEO | $220k 9,500 shares | -2% | |
| 10Weak | Monte Rosa Therapeutics, Inc. | Jennifer Champoux Chief Operating Officer | $102k 4,351 shares | -7% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Sharon Townson Chief Scientific Officer | $140k 6,000 shares | -8% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Filip Janku Chief Medical Officer | $132k 5,407 shares | -8% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Filip Janku Chief Medical Officer | $138k 6,000 shares | -9% | |
| 48Moderate | Monte Rosa Therapeutics, Inc. | Anthony M. Manning director | $231k 10,000 shares | -100% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Jennifer Champoux Chief Operating Officer | $44k 2,175 shares | -3% | |
| 2Weak | Monte Rosa Therapeutics, Inc. | Sharon Townson Chief Scientific Officer | $60k 3,000 shares | -4% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Jennifer Champoux Chief Operating Officer | $41k 2,176 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.